对于慢性运动对胰岛素敏感的影响,GDF15是不可或缺的
Axel Labour1, Marlène Lac1, Lucas Frassin1
1Institute of Metabolic and Cardiovascular Diseases, INSERM/Paul Sabatier University, UMR1297, Toulouse, France.
Cell reports
|August 3, 2024
概括
增长和分化因子15 (GDF15) 不需要炼以改善胰岛素敏感性. 在小鼠和人类的研究表明,无论GDF15水平如何,运动都有利于葡萄糖耐受性和胰岛素敏感性.
科学领域:
- 代谢健康 代谢健康
- 运动生理学 运动生理学
- 内分泌学 在内分泌学.
背景情况:
- 增长与差异化因子15 (GDF15) 被公认为其在体重管理和胰岛素敏感性方面的作用.
- 此外,GDF15还被认为是一种由压力引起的信号,特别是在对运动的反应中.
- 对于运动的代谢益处,GDF15的必要性仍然不清楚.
研究的目的:
- 调查GDF15是否对运动的胰岛素敏感作用至关重要.
- 检查GDF15在运动诱导的小鼠和人类葡萄糖代谢改善中的作用.
主要方法:
- 在标准和高脂肪饮食下使用GDF15淘汰赛 (KO) 和野生型 (WT) 鼠标.
- 评估葡萄糖耐受性,全身胰岛素敏感性和运动能力 (最大速度,耐力跑步).
- 对瘦身和肥胖的小鼠进行了为期4周的运动训练计划,并分析了人类的反应.
主要成果:
- 与WT littermates相比,GDF15 KO小鼠表现出正常的基线葡萄糖耐受性,胰岛素敏感性和运动能力.
- 运动训练同样提高了WT和GDF15KO小鼠 (瘦和肥胖) 的耐力,葡萄糖耐受性,胰岛素敏感性和外周葡萄糖吸收.
- 在人体中,运动训练对胰岛素敏感的影响与血GDF15水平无关.
结论:
- GDF15对于慢性运动引起的胰岛素敏感性适应是不可或缺的.
- 运动通过GDF15独立的途径改善了代谢参数,如耐葡萄糖和胰岛素敏感性.
- 这些发现澄清了运动的健康益处背后的分子机制.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
162
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
162
Glucagon-like Receptor Agonists
311
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
311
Oral Hypoglycemic Agents: Biguanides and Glitazones
185
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
185
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
Oral Hypoglycemic Agents: Glinides
150
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
150
Hormones Regulating Blood Glucose
3.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.2K


